AbbVie's aiming to make the most out of its new moneymaker Botox, gained in its Allergan megamerger last year, and it just scored a legal win—against ...

MacroGenics’ oncology med Margenza is launching into the crowded HER2-positive breast cancer field. But the company has one advantage it can tout: The drug topped Ro...

About a month after the FDA issued emergency authorizations for COVID-19 antibodies from Eli Lilly and Regeneron, most of them have gone unused, a federal official s...

Over the last few years, the federal government has inked charity kickback settlements with a who’s who of pharma companies. With a new Department of Justice settlem...

As BioNTech makes inroads with Pfizer for their COVID-19 vaccine in the Western world, the German biotech has agreed to supply 100 million doses for its Chinese...

Novartis’ Entresto chalked up a high-profile flop in a heart failure study last year, but the Swiss pharma shot for an FDA approval anyway. Now, reviewers at the age...

What if public health officials could track mental health crises as they happen? A new Mental Health America dashboard backed by Lundbeck looks to do just ...

As the COVID-19 crisis began to take hold in the U.S. earlier this year, healthcare systems scrambled to treat critically ill patients in an unknown landscape. Tho...